Somatuline Depot (Lanreotide)
Purpose of Medication and Method of Action
Somatuline Depot from Beaufour Ipsen/Tercica-Somatuline is indicated for the long-term treatment of acromegly, a disease characterized by the excess secretion of growth hormone (HGH). This new drug acts by lowering levels of growth hormone and insulin-like growth factor. Excess blood levels of those two biochemicals results in enlargement of hands, feet, facial bones and internal organs.
Usual Dose
Somatuline is given by subcutaneous injection every four weeks and is indicated for patients who have not responded well to surgery or radiotherapy.
Patient Medication Information
These information sheets do not list all known side effects of the medications, only the most common side effects. For a complete list of side effects please contact your local pharmacy or the actual drug manufacturing company.